From: Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy
 | A. Cox regression analysis of association between clinicopathologic variables and overall survival | B. Binary logistic regression analysis of association between clinicopathologic variables and tumor-response status | ||||||
---|---|---|---|---|---|---|---|---|
Variablesa | P-value | HR | 95Â % CI | P-value | OR | 95Â % CI | ||
Age | 0.973 | Â | Â | Â | 0.126 | Â | Â | Â |
<10 years | 0.829 | 0.000 | 0.000 | ∞ | 0.043 | 0.006 | 0.000 | 0.845 |
10–24 years | 0.922 | 0.876 | 0.063 | 12.227 | 0.084 | 0.012 | 0.000 | 1.814 |
Gender | 0.122 | 4.390 | 0.674 | 28.596 | 0.609 | 2.189 | 0.109 | 44.045 |
Location | 0.972 | Â | Â | Â | 0.601 | Â | Â | Â |
Tibia/ fibula/calcaneus | 0.743 | 0.000 | 0.000 | ∞ | 0.999 | 6.119E9 | 0.000 | ∞ |
Femur | 0.737 | 0.000 | 0.000 | ∞ | 0.999 | 4.232E9 | 0.000 | ∞ |
Humerus/ulna | 0.719 | 0.000 | 0.000 | ∞ | 0.999 | 5.229E10 | 0.000 | ∞ |
Histological subtype | 0.902 | Â | Â | Â | 0.935 | Â | Â | Â |
Chondroblastic | 0.986 | 0.139 | 0.000 | ∞ | 0.999 | 8.367E8 | 0.000 | ∞ |
Fibroblastic | 0.922 | 22186 | 0.000 | ∞ | 0.999 | 0.000 | 0.000 | ∞ |
Osteoblastic | 0.932 | 6308 | 0.000 | ∞ | 0.514 | 5.300 | 0.036 | 789.165 |
RX P16 negative (n = 39) | 0.003 | 0.067 | 0.011 | 0.397 | 0.004 | 74.076 | 3.875 | 1415.946 |
RX P53 negative (n = 44) | 0.315 | 0.515 | 0.141 | 1.879 | 0.159 | 4.786 | 0.541 | 42.368 |
RX PTEN negative (n = 22) | 0.166 | 5.342 | 0.498 | 57.310 | 0.999 | 2.169E9 | 0.000 | ∞ |
RX Maspin negative (n = 33) | 0.409 | 0.482 | 0.085 | 2.725 | 0.192 | 4.384 | 0.477 | 40.278 |
RX Ki67 negative (n = 25) | 0.069 | 0.157 | 0.021 | 1.157 | 0.999 | 1.934E9 | 0.000 | ∞ |
RX BMI1 negative (n = 28) | 0.353 | 3.624 | 0.239 | 54.951 | 1.000 | 0.000 | 0.000 | ∞ |